LONDON, May 14, 2013
/PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM:
GWP, "GW" or "the Company"), a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform, will be announcing
interim financial results for the six months ended 31 March
2013 on Monday, 3 June 2013, prior to the UK
stock market open. GW will also host a conference call the same day
at 1:00 p.m. BST (8:00 a.m. EDT). GW is currently in a "quiet
period" due to the Company's recent Initial Public Offering of
American Depository Shares on the Nasdaq Capital Market exchange
and has decided to hold its Interim results presentation after the
expiration of this quiet period.
Conference call information will be provided in the interim
financial results press release. A replay of the call will also be
available through the Company's website (www.gwpharm.com) shortly
after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW
commercialized the world's first plant-derived cannabinoid
prescription drug, Sativex®, which is approved for the treatment of
spasticity due to multiple sclerosis in 21 countries. Sativex is
also in Phase 3 clinical development as a potential treatment of
pain in people with advanced cancer. This Phase 3 program is
intended to support the submission of a New Drug Application for
Sativex in cancer pain with the U.S. Food and Drug Administration
and in other markets around the world. GW has established a world
leading position in the development of plant-derived cannabinoid
therapeutics and has a deep pipeline of additional cannabinoid
product candidates, including two distinct compounds, GWP42004 and
GWP42003, in Phase 2 clinical development for Type 2 diabetes and
ulcerative colitis, respectively, and at least two additional
programs expected to enter Phase 1 and Phase 2 clinical trials in
the next 12 months. For further information, please visit
www.gwpharm.com.
SOURCE GW Pharmaceuticals plc